Søren Bregenholt
Vorstandsvorsitzender bei ALLIGATOR BIOSCIENCE AB
Vermögen: 74 485 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Hans-Peter Albert Ostler | M | 53 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 3 Jahre |
Marie Svensson | F | 60 |
A Bioscience Incentive AB
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | 4 Jahre |
Malin Carlsson | M | 56 |
A Bioscience Incentive AB
| 4 Jahre |
Anders Olof Adolf Ekblom | M | 70 | 7 Jahre | |
Lennart Erik Jonas Sjögren | M | 58 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 7 Jahre |
Laura Ila von Schantz | M | 42 | 10 Jahre | |
Eva Ulrika Sjökvist Saers | M | 62 | 3 Jahre | |
Peter Ellmark | M | 51 | 6 Jahre | |
Christina Furebring | M | 60 |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013.
A Bioscience Incentive AB
| - |
Denise Goode | F | 66 | 2 Jahre | |
Eva Sjökvist Saers | M | 62 | - | |
Sumeet Ambarkhane | M | 56 | 2 Jahre | |
Daniel Johnsson | M | 56 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Christer Nordstedt | M | 62 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | 2 Jahre |
Sven Fredrik Tiberg | M | 61 |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | - |
Per-Olof Schrewelius | M | 61 |
A Bioscience Incentive AB
| - |
Per Norlén | M | 54 |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | - |
Marianne Dicander Alexandersson | F | 65 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Peter Jens Lindholm Kurtzhals | M | - |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | - |
Alistair Bone | M | - |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | - |
Daniel Spasic | M | - |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | - |
Claes Tomas Post | M | 74 |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Staffan Encrantz | M | 73 | 2 Jahre | |
Mats Lindskog | M | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Peter James Arthur Benson | M | 69 | 10 Jahre | |
Karl Arne Krister Borrebaeck | M | 76 | 20 Jahre | |
Kenth Ingemar Petersson | M | 68 | 20 Jahre | |
Graham Dixon | M | 63 | 5 Jahre | |
Kirsten Drejer | M | 68 | 2 Jahre | |
Anna Ulrika Danielsson | F | 52 | 5 Jahre | |
Julie Silber | F | 56 | - | |
Veronica Wallin | F | 38 | 3 Jahre | |
Tova Landström | M | - | - | |
Gayle Mills | F | 69 | 1 Jahre | |
Anette Sundstedt | M | 57 | 3 Jahre | |
Christina Reimer | M | 52 | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweden | 32 | 88,89% |
Dänemark | 4 | 11,11% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Søren Bregenholt
- Persönliches Netzwerk